← Back to Search

Executive Function Training Program for Ischemic White Matter Disease

N/A
Waitlist Available
Led By Gary Turner, PhD
Research Sponsored by Baycrest
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and follow-up at 2 months
Awards & highlights

Study Summary

Stroke is a leading cause of disability; most strokes (80%) are subcortical, with ischemic damage due to occlusion in penetrating arteries. Although ischemic white matter disease (iWMD) may lack gross clinical manifestation, it causes significant cognitive impairment, particularly on measures of executive function, attention, and memory. This impairment is attributable to diffuse damage affecting network connections. While there are many studies concerning rehabilitation of motor function and language in patients with large focal strokes, few studies have addressed attentional and executive functions. To our knowledge, there are no such studies on iWMD. In this study, patients will be randomized to a novel intervention for improving executive function and a control condition matched for therapist exposure. Patients will be assessed pre-intervention, post-intervention, and at long-term follow-up using a battery of behavioural and neuroimaging tasks. We predict that the novel intervention will be associated with improved executive function, as assessed behaviourally, and improved frontal network function, as assessed through neuroimaging markers.

Eligible Conditions
  • Stroke Risk
  • Ischemic White Matter Disease
  • Mini Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and follow-up at 2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and follow-up at 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in neuropsychological test performance at 2 month follow-up
Change from baseline in neuropsychological test performance at post-intervention
Secondary outcome measures
Change from baseline in neuroimaging (fMRI/EEG) markers at 2 month follow-up
Change from baseline in neuroimaging (fMRI/EEG) markers at post-intervention

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Executive Function Training ProgramExperimental Treatment1 Intervention
Participants in this group will receive the novel intervention training.
Group II: Psychoeducational Training ProgramActive Control1 Intervention
Participants in this group will receive the control intervention training.

Find a Location

Who is running the clinical trial?

BaycrestLead Sponsor
43 Previous Clinical Trials
5,927 Total Patients Enrolled
Sunnybrook Health Sciences CentreOTHER
656 Previous Clinical Trials
1,551,268 Total Patients Enrolled
Gary Turner, PhDPrincipal InvestigatorSunnybrook Health Sciences Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025